514170-00-4

Upstream product

• 110-85-0 piperazine 
• 139029-71-3 2,4-dichloro-benzhydryl chloride 

Downstream Products

• 1094790-66-5 C₂₃H₂₆Cl₂N₂O 
• 1094791-25-9 4-[(2,4-dichlorophenyl)(phenyl)methyl]-N-piperidin-1-ylpiperazine-1-carboxamide 
• 1094790-71-2 C₂₈H₃₂Cl₂N₂O 
• 1094790-80-3 N-cyclohexyl-4-[(2,4-dichlorophenyl)(phenyl)methyl]piperazine-1-carboxamide 
• 1094790-68-7 1-(cyclohexylcarbonyl)-4-[(2,4-dichlorophenyl)(phenyl)methyl]piperazine 
• 1094790-78-9 N-butyl-4-[(2,4-dichlorophenyl)(phenyl)methyl]piperazine-1-carboxamide 
• 1094790-82-5 N-cyclohexyl-4-[(2,4-dichlorophenyl)(phenyl)methyl]piperazine-1-carbothioamide 
• 1094790-64-3 C₂₂H₂₄Cl₂N₂O 
• 661453-46-9 C₃₂H₃₀Cl₂N₂O 
• 866562-67-6 2-{4-[(2,4-dichloro-phenyl)-phenyl-methyl]-piperazin-1-yl}-N,N-diphenyl-acetamide 
• 878162-08-4 4-[(2,4-dichloro-phenyl)-phenyl-methyl]-piperazine-1-carboxylic acid benzhydryl-amide 
• 866562-50-7 1-{4-[(2,4-dichloro-phenyl)-phenyl-methyl]-piperazin-1-yl}-2-diphenylamino-ethanone 

Relevant academic research and scientific papers

Discovery of benzhydrylpiperazine derivatives as CB1 receptor inverse agonists via privileged structure-based approach

The present study describes the identification via privileged structure-based approach of the benzhydrylpiperazine moiety as a potential scaffold to develop novel CB1 receptor modulators. Efficient structural optimization of the initial four hit compounds led to a high quality lead series, represented by compound 6c. Compound 6c is a highly potent and selective CB1 receptor inverse agonist that is able to reduce body weight in diet-induced obese Sprague-Dawley rats. The preparation of privileged structure-based library, the progression from hit to lead, the structure-activity relationships in the lead series and in vitro and in vivo activity of compound 6c are discussed.

Structure-activity relationships of diphenylpiperazine N-type calcium channel inhibitors

A novel series of compounds derived from the previously reported N-type calcium channel blocker NP118809 (1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one) is described. Extensive SAR studies resulted in compounds with IC50 values in the range of 10-150 nM and selectivity over the L-type channels up to nearly 1200-fold. Orally administered compounds 5 and 21 exhibited both anti-allodynic and anti-hyperalgesic activity in the spinal nerve ligation model of neuropathic pain.